Lorraine Kalia - Publications

2009-2010 Neurology MGH & Harvard Medical School, Boston, MA, United States 

23 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Chen KS, Menezes K, Rodgers JB, O'Hara DM, Tran N, Fujisawa K, Ishikura S, Khodaei S, Chau H, Cranston A, Kapadia M, Pawar G, Ping S, Krizus A, Lacoste A, ... ... Kalia LV, et al. Small molecule inhibitors of α-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans. Molecular Neurodegeneration. 16: 77. PMID 34772429 DOI: 10.1186/s13024-021-00497-6  0.336
2020 Mylvaganam S, Earnshaw R, Heymann G, Kalia SK, Kalia LV. C-terminus of Hsp70 Interacting Protein (CHIP) and Neurodegeneration: Lessons from the Bench and Bedside. Current Neuropharmacology. PMID 33200713 DOI: 10.2174/1570159X18666201116145507  0.309
2020 Friesen EL, Zhang YT, Earnshaw R, De Snoo ML, O'Hara DM, Agapova V, Chau H, Ngana S, Chen KS, Kalia LV, Kalia SK. BAG5 Promotes Alpha-Synuclein Oligomer Formation and Functionally Interacts With the Autophagy Adaptor Protein p62. Frontiers in Cell and Developmental Biology. 8: 716. PMID 32850835 DOI: 10.3389/fcell.2020.00716  0.308
2020 O'Hara DM, Pawar G, Kalia SK, Kalia LV. LRRK2 and α-Synuclein: Distinct or Synergistic Players in Parkinson's Disease? Frontiers in Neuroscience. 14: 577. PMID 32625052 DOI: 10.3389/fnins.2020.00577  0.378
2020 Maclagan LC, Visanji NP, Cheng Y, Tadrous M, Lacoste AMB, Kalia LV, Bronskill SE, Marras C. Identifying drugs with disease-modifying potential in Parkinson's disease using artificial intelligence and pharmacoepidemiology. Pharmacoepidemiology and Drug Safety. PMID 32410265 DOI: 10.1002/Pds.5015  0.321
2020 O'Hara DM, Kalia SK, Kalia LV. Methods for detecting toxic α-synuclein species as a biomarker for Parkinson's disease. Critical Reviews in Clinical Laboratory Sciences. 1-17. PMID 32116096 DOI: 10.1080/10408363.2019.1711359  0.383
2020 Espay AJ, Kalia LV, Gan-Or Z, Williams-Gray CH, Bedard PL, Rowe SM, Morgante F, Fasano A, Stecher B, Kauffman MA, Farrer MJ, Coffey CS, Schwarzschild MA, Sherer T, Postuma RB, et al. Disease modification and biomarker development in Parkinson disease: Revision or reconstruction? Neurology. PMID 32102975 DOI: 10.1212/Wnl.0000000000009107  0.369
2020 McKinnon C, De Snoo ML, Gondard E, Neudorfer C, Chau H, Ngana SG, O'Hara DM, Brotchie JM, Koprich JB, Lozano AM, Kalia LV, Kalia SK. Early-onset impairment of the ubiquitin-proteasome system in dopaminergic neurons caused by α-synuclein. Acta Neuropathologica Communications. 8: 17. PMID 32059750 DOI: 10.1186/s40478-020-0894-0  0.351
2018 Kalia LV. Diagnostic biomarkers for Parkinson's disease: focus on α-synuclein in cerebrospinal fluid. Parkinsonism & Related Disorders. PMID 30466800 DOI: 10.1016/j.parkreldis.2018.11.016  0.367
2018 Hara DMO, Kalia SK, Kalia LV. Emerging Disease-Modifying Strategies Targeting α-Synuclein for the Treatment of Parkinson Disease. British Journal of Pharmacology. PMID 29722028 DOI: 10.1111/bph.14345  0.366
2017 Friesen EL, De Snoo ML, Rajendran L, Kalia LV, Kalia SK. Chaperone-Based Therapies for Disease Modification in Parkinson's Disease. Parkinson's Disease. 2017: 5015307. PMID 28913005 DOI: 10.1155/2017/5015307  0.371
2017 Koprich JB, Kalia LV, Brotchie JM. Animal models of α-synucleinopathy for Parkinson disease drug development. Nature Reviews. Neuroscience. PMID 28747776 DOI: 10.1038/nrn.2017.75  0.343
2017 Rosborough K, Patel N, Kalia LV. α-Synuclein and Parkinsonism: Updates and Future Perspectives. Current Neurology and Neuroscience Reports. 17: 31. PMID 28324300 DOI: 10.1007/s11910-017-0737-y  0.388
2016 Visanji NP, Brotchie JM, Kalia LV, Koprich JB, Tandon A, Watts JC, Lang AE. α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era. Trends in Neurosciences. PMID 27776749 DOI: 10.1016/J.Tins.2016.09.003  0.38
2016 Rowland NC, Kalia SK, Kalia LV, Larson PS, Lim DA, Bankiewicz KS. Merging DBS with viral vector or stem cell implantation: "hybrid" stereotactic surgery as an evolution in the surgical treatment of Parkinson's disease. Molecular Therapy. Methods & Clinical Development. 3: 15051. PMID 26817024 DOI: 10.1038/Mtm.2015.51  0.324
2015 Kalia LV, Kalia SK, Lang AE. Disease-modifying strategies for Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 30: 1442-50. PMID 26208210 DOI: 10.1002/mds.26354  0.347
2015 Kalia LV, Kalia SK. α-Synuclein and Lewy pathology in Parkinson's disease. Current Opinion in Neurology. 28: 375-81. PMID 26110807 DOI: 10.1097/WCO.0000000000000215  0.374
2015 Kalia LV, Lang AE. Parkinson's disease. Lancet. PMID 25904081 DOI: 10.1016/S0140-6736(14)61393-3  0.364
2014 Beilina A, Rudenko IN, Kaganovich A, Civiero L, Chau H, Kalia SK, Kalia LV, Lobbestael E, Chia R, Ndukwe K, Ding J, Nalls MA, Olszewski M, et al. Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. Proceedings of the National Academy of Sciences of the United States of America. 111: 2626-31. PMID 24510904 DOI: 10.1073/Pnas.1318306111  0.306
2014 AlDakheel A, Kalia LV, Lang AE. Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 11: 6-23. PMID 24085420 DOI: 10.1007/s13311-013-0218-1  0.325
2013 Dimant H, Kalia SK, Kalia LV, Zhu LN, Kibuuka L, Ebrahimi-Fakhari D, McFarland NR, Fan Z, Hyman BT, McLean PJ. Direct detection of alpha synuclein oligomers in vivo. Acta Neuropathologica Communications. 1: 6. PMID 24252244 DOI: 10.1186/2051-5960-1-6  0.748
2013 Kalia LV, Kalia SK, McLean PJ, Lozano AM, Lang AE. α-Synuclein oligomers and clinical implications for Parkinson disease. Annals of Neurology. 73: 155-69. PMID 23225525 DOI: 10.1002/Ana.23746  0.652
2011 Kalia LV, Kalia SK, Chau H, Lozano AM, Hyman BT, McLean PJ. Ubiquitinylation of α-synuclein by carboxyl terminus Hsp70-interacting protein (CHIP) is regulated by Bcl-2-associated athanogene 5 (BAG5). Plos One. 6: e14695. PMID 21358815 DOI: 10.1371/Journal.Pone.0014695  0.68
Show low-probability matches.